Wockhardt Ltd (WOCKPHARMA)

Wockhardt's New Antibiotic Drug Shows Promise in Trials - 06 Jul, 2024

Wockhardt's new antibiotic drug, Zaynich, has shown promising results in trials and has the potential to act against all major superbugs. The drug is currently undergoing global phase three clinical trials, which are expected to be complete by this fiscal year. The company expects to receive global approval for launching Zaynich in FY26.

Wockhardt Ltd's Stock on the Rise After Skipping Phase Two in FDA Approval - 05 Jul, 2024

Wockhardt Ltd's stock is seeing a surge after being allowed to skip phase two and move directly into phase three of drug approval by the US FDA. Analysts predict early commercialization due to the large market size and Wockhardt's sole player status.

Wockhardt Shares Surge on Promising Antibiotics - 04 Jul, 2024

Wockhardt Ltd's stock has surged by 84% in a month due to positive news surrounding the company's upcoming launches of two blockbuster antibiotics. The drugs are expected to change the course of the drugmaker's earnings trajectory. Additionally, the company plans to enter the biosimilar space in the next 3-4 years and expand its product portfolio.

Wockhardt Shares Surge on Promising Antibiotics - 03 Jul, 2024

Shares of Wockhardt Ltd have surged close to 40% in five consecutive sessions, hitting a 52-week high of Rs 943 on July 3 due to bullishness over the company's two promising antibiotics heading closer to launch in India. The drugmaker has applied for approval from the Drug Controller General of India for Nafithromycin and aims to enter a market valued at $1.5 billion annually in developed countries and $263 million in developing countries.

Wockhardt Stock Surges on Successful Use of Investigational Antibiotic - 02 Jul, 2024

Wockhardt's investigational antibiotic, Zaynich, successfully treated a cancer patient in the US, leading to a surge in stock prices. The drug is expected to be launched at a steep discount next financial year. Wockhardt plans to expand its portfolio to include biologicals, new insulins, and other diabetic products.

Wockhardt Shares Surge on Successful Use of Antibiotic Drug - 01 Jul, 2024

Wockhardt Ltd's stock price surges up to 20% following the successful use of its investigational antibiotic, Zaynich, to treat a cancer patient in the US. The company is also planning to launch Zaynich at a significant discount and expand its product portfolio. Revenues rose 5.5% YoY while net losses declined. Wockhardt shares have given multibagger returns over the past year.

Wockhardt Ltd Stock Surges 28% - 30 Jun, 2024

Shares of Wockhardt Ltd have gained 28% in a month, with an annual gain of 192%. The company's reasonable revenue growth has increased investors' willingness to pay for the stock.

Wockhardt Plans Launch of Novel Antibiotic Candidate Zaynich - 28 Jun, 2024

Wockhardt is set to launch its novel antibiotic candidate Zaynich in India by end of FY25, followed by a global launch in FY26. The drug has no competition worldwide for at least the next 15 years and is expected to impact the company's revenue and growth prospects positively. Additionally, the company announced successful use of Zaynich to treat a cancer patient in the US.

Wockhardt CEO's Compensation 45% Less Than Industry Average - 22 Jun, 2024

Wockhardt Ltd CEO Murtaza Khorakiwala's total compensation is 45% less than the industry average. The company's past three-year shareholder return was 11%, but EPS decline and low revenue growth are concerning. Shareholders may not want to see high CEO compensation.

Wockhardt Ltd Reports 3.24% YoY Increase in Net Sales - 18 Jun, 2024

Wockhardt Ltd's consolidated net sales for March 2024 stood at Rs. 700 crore, up by 3.24% YoY. However, the company reported a quarterly net loss of Rs. 169 crore in March 2024, an increase of 18.75% from the previous year. The EBITDA also decreased to negative Rs. 49 crore in March 2024.